Harmony Biosciences Holdings (HRMY) Cash from Operations (2019 - 2026)

Harmony Biosciences Holdings has disclosed Cash from Operations across 8 years of filings, most recently posting 27760000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 27760000.0, down 18.32% year-over-year; the trailing twelve-month figure through Mar 2026 was 341972000.0 (up 53.58% YoY), and the FY2025 annual result was 348199000.0, up 58.4% from the prior year.
• Cash from Operations came in at 27760000.0 for Q1 2026 at Harmony Biosciences Holdings, down from 126151000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 126151000.0 in Q4 2025 to a low of 26678000.0 in Q4 2022.
• The 5-year median for Cash from Operations is 42617000.0 (2024), against an average of 56449000.0.
• Across the five-year window, Cash from Operations retreated 28.92% in 2022 and soared 187.37% in 2023, its largest moves.
• Harmony Biosciences Holdings' Cash from Operations stood at 26678000.0 in 2022, then jumped by 187.37% to 76665000.0 in 2023, then fell by 1.44% to 75562000.0 in 2024, then surged by 66.95% to 126151000.0 in 2025, then slumped by 77.99% to 27760000.0 in 2026.
• The last three Cash from Operations figures came in at 27760000.0 (Q1 2026), 126151000.0 (Q4 2025), and 108734000.0 (Q3 2025), per Business Quant data.